NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/22/23 | 8-K | Current report filing |
|
   |
7 |
| 05/22/23 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
35 |
| 05/18/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 05/16/23 | NT 10-Q | Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB |
|
2 | |
| 04/28/23 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/28/23 | DEF 14A | Definitive proxy statements |
|
58 | |
| 03/31/23 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
113 |
| 03/29/23 | 8-K | Current report filing |
|
|
7 |
| 03/01/23 | 4/A | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/23/23 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |